Skip to content

Evaluation of Intestinal Bacterial and Fungal Translocation and Intestinal Microbiota in Febrile Neutropenic Patients in Pediatric Onco-hematology

Evaluation of Intestinal Bacterial and Fungal Translocation and Intestinal Microbiota in Febrile Neutropenic Patients in Pediatric Onco-hematology

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03342365
Acronym
TRANSNEUTROFEB
Enrollment
10
Registered
2017-11-14
Start date
2018-04-13
Completion date
2018-12-29
Last updated
2021-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Febrile Neutropenia

Brief summary

This pilot study aims to study intestinal bacterial and fungal translocation and the evolution of the intestinal microbiota in patients over the course of their medical surveillance to search for a link between dysbiosis and bacterial/fungal translocation, but also to better understand the elements involved in febrile episodes in these patients (lack of detection of blood microorganisms, translocation of constituent elements of these microorganisms, etc.). We hypothesize that the composition of the intestinal microbiota as well as the phenomenon of intestinal microbial translocation will have an influence on the occurrence of fever and/or bacteremia in neutropenic patients hospitalized in pediatric onco-hematology.

Interventions

DIAGNOSTIC_TESTEvaluation of microbial translocation and microbiota

Blood test from catheter already in place to determine microbial translocation and stool sample taken for microbiota analysis

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 20 Years
Healthy volunteers
No

Inclusion criteria

* Inclusion Criteria: * Information concerning the study set-up, objectives, constraints and the patient's rights is transmitted * The patient and/or their legal guardian must have given their free and informed consent. If the patient is over 18, it is the patient who signs the consent form * The patient must be a member or beneficiary of a health insurance plan *

Exclusion criteria

* The patient is under state guardianship or safeguard of justice * Refusal to sign the consent * It is impossible to give the subject informed information * Pregnant, parturient or breast feeding patient

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the effect of presence of bacterial and fungal translocation on occurrence of episodes of febrile neutropenia in pediatric onco-hematology patients.Between day 7-15Presence or absence of microbial translocation; presence = ≥ 10 copies of rDNA16S/µL and/or ≥ 1 copies rDNA 18S/µL and ≥10 ng/mL LBP, ≥10 ng/mL of sCD14 and ≥5 ng/mL of zonulin.

Secondary

MeasureTime frameDescription
Evaluate prognostic quality of fungal and bacterial translocation markers in occurrence of episodes of febrile neutropenia in bacteremic patientsBetween day 7-15
Compare bacterial and fungal translocation kinetics in febrile neutropenic patients of unknown origin versus bacteremic patientsBetween day 7-15
Evaluate prognostic quality of fungal and bacterial translocation markers in occurrence of episodes of febrile neutropenia of unknown originBetween day 7-15
Describe the kinetics of markers and intestinal microbial phylogenetic compositions according to the bioclinical characteristics of the populationBetween day 7-15Diversity defined by number of different species and number of different taxonomic groups
Creation of biobankend of study day 30All blood and stool samples taken from patients who develop neutropenia. Patients who do not develop neutropenia will have their samples collected at inclusion destroyed
Compare direct (16S rDNA, 18S rDNA) versus indirect (LBP, sCD14 and plasma zonulin) measures of translocation and association with bioclinical characteristics of the populationBetween day 7-15

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026